Loading clinical trials...
Loading clinical trials...
A Phase 3, Parallel Group, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
Conditions
Interventions
SPM 907
Locations
1
Germany
Schwarz
Monheim, Germany
Start Date
January 1, 2004
Primary Completion Date
February 1, 2005
Completion Date
February 1, 2005
Last Updated
May 5, 2008
NCT04873037
NCT06198439
NCT06769854
NCT03535857
NCT06616675
NCT05719285
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions